Anticancer effects of isofraxidin against A549 human lung cancer cells via the EGFR signaling pathway

Zhang,Han; Feng,Qian‑Qian; Gong,Jian‑Hua; Ma,Jing‑Ping

doi:10.3892/mmr.2018.8950

Anticancer effects of isofraxidin against A549 human lung cancer cells via the EGFR signaling pathway

Authors:
- Han Zhang
- Qian‑Qian Feng
- Jian‑Hua Gong
- Jing‑Ping Ma
View Affiliations

Affiliations: Breath Internal Medicine Department, The Second Clinical Medical College, Jingzhou Central Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and Yangtze University, Jingzhou, Hubei 434100, P.R. China
Published online on: May 3, 2018 https://doi.org/10.3892/mmr.2018.8950
Pages: 407-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of mortality due to tumor malignancy worldwide. In recent years, the treatment of lung cancer with chemotherapy has demonstrated notable resistance and insensitivity. Therefore, it is of great importance to investigate anti‑lung cancer drugs with high efficiency and low toxicity. In the present study, the effects of isofraxidin on lung cancer cells and the associated mechanisms were investigated. The results revealed that, in vivo and in vitro, isofraxidin exhibited marked inhibitory effects on the A549 lung cancer cell line. The results of Cell Counting kit‑8, Transwell migration and Matrigel invasion assays, and flow cytometry to determine apoptosis, revealed that isofraxidin significantly inhibited the proliferation, migration and invasion of A549 cells, and induced the cell apoptosis. Furthermore, western blot analysis demonstrated that isofraxidin treatment led to effects on the expression of apoptosis‑associated proteins, including members of the Bcl‑2 protein family, and invasion‑associated proteins, including matrix metallopeptidase (MMP)‑2 and MMP‑9, which may occur via inhibition of the expression of phosphorylated (p)‑epidermal growth factor receptor, p‑AKT and p‑extracellular signal‑regulated kinase. This regulation of protein expression may contribute to the inhibition of proliferation, migration and invasion of A549lung cancer cells by isofraxidin. In addition, despite the inhibitory effects on the A549 lung cancer cell line, the present study revealed that isofraxidin exhibited low toxicity towards BEAS‑2B normal lung epithelial cells within a certain dose range (0‑160 µM), indicating that isofraxidin may be employed for lung cancer treatment with hypotoxicity and fewer side effects. In conclusion, isofraxidin may be a novel candidate for anti‑lung cancer chemotherapy.

View Figures

View References

1	Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10. 2011. View Article : Google Scholar : PubMed/NCBI
2	Lamb YN and Scott LJ: Osimertinib: A review in T790M-positive advanced non-small cell lung cancer. Target Oncol. 12:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
3	Goss GD and Spaans JN: Epidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lung. Oncologist. 21:205–213. 2016. View Article : Google Scholar : PubMed/NCBI
4	Salmenkivi K and Knuuttila A: Diagnostics of non-small cell lung carcinoma. Duodecim. 130:701–704. 2014.(In Finnish). PubMed/NCBI
5	Rosenzweig K: Stereotactic body radiation therapy as an alternative to surgery in early-stage non-small-cell lung cancer. Oncology (Williston Park). 31:492–498. 2017.PubMed/NCBI
6	Wan Y, Yuan Y, Pan Y and Zhang Y: Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Exp Ther Med. 13:3067–3074. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhang K and Yuan Q: Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 12 Suppl:C131–C137. 2016. View Article : Google Scholar : PubMed/NCBI
8	Pan L, Chai H and Kinghorn AD: The continuing search for antitumor agents from higher plants. Phytochem Lett. 3:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
9	Shen P, Wang HG, Li MM, Ma QY, Zhou CW, Pan F and Xie R: Isofraxidin inhibited proliferation and induced apoptosis via blockage of Akt pathway in human colorectal cancer cells. Biomed Pharmacother. 92:78–85. 2017. View Article : Google Scholar : PubMed/NCBI
10	Niu X, Xing W, Li W, Fan T, Hu H and Li Y: Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway. Int Immunopharmacol. 14:164–171. 2012. View Article : Google Scholar : PubMed/NCBI
11	Khan S, Riaz N, Afza N, Malik A, Aziz-ur-Rehman, Iqbal L and Lateef M: Antioxidant constituents from Cotoneaster racemiflora. J Asian Nat Prod Res. 11:44–48. 2009. View Article : Google Scholar : PubMed/NCBI
12	Deyama T, Nishibe S and Nakazawa Y: Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacol Sin. 22:1057–1070. 2001.PubMed/NCBI
13	Yamazaki T and Tokiwa T: Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits matrix metalloproteinase-7 expression and cell invasion of human hepatoma cells. Biol Pharm Bull. 33:1716–1722. 2010. View Article : Google Scholar : PubMed/NCBI
14	Qian L, Li X, Ye P, Wang G, Dai W, Liu Y, Gao Q and Shen G: Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway. Cytotechnology. 70:83–94. 2018. View Article : Google Scholar : PubMed/NCBI
15	Hu S, Ran Y, Chen W, Zhang Y and Xu Y: MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1. Oncol Rep. 38:1569–1578. 2017. View Article : Google Scholar : PubMed/NCBI
16	Bai L, Lin G, Sun L, Liu Y, Huang X, Cao C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Wan D, Zhou R, Zhong W, Lu S and Chai Y: Geraniin inhibits migration and invasion of human osteosarcoma cancer cells through regulation of PI3K/Akt and ERK1/2 signaling pathways. Anticancer Drugs. 28:959–966. 2017. View Article : Google Scholar : PubMed/NCBI
18	Li W, Sun D, Lv Z, Wei Y, Zheng L, Zeng T and Zhao J: Insulin-like growth factor binding protein-4 inhibits cell growth, migration and invasion, and downregulates COX-2 expression in A549 lung cancer cells. Cell Biol Int. 41:384–391. 2017. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Ge C, Zhao F, Zhang Y, Wang X, Yao M and Li J: NRBP2 overexpression increases the chemosensitivity of hepatocellular carcinoma cells via Akt signaling. Cancer Res. 76:7059–7071. 2016. View Article : Google Scholar : PubMed/NCBI
20	Niu X, Wang Y, Li W, Mu Q, Li H, Yao H and Zhang H: Protective effects of Isofraxidin against lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 24:432–439. 2015. View Article : Google Scholar : PubMed/NCBI
21	Edlich F: BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochem Biophys Res Commun. Jul 1–2017.(Epub ahead of print). PubMed/NCBI
22	Zhou L, Cai X, Han X, Xu N and Chang DC: CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents. Cell Biol Int. 38:737–746. 2014. View Article : Google Scholar : PubMed/NCBI
23	Spencer SL and Sorger PK: Measuring and modeling apoptosis in single cells. Cell. 144:926–939. 2011. View Article : Google Scholar : PubMed/NCBI
24	Hu X, Li D, Zhang W, Zhou J, Tang B and Li L: Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 286:1537–1543. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
26	Wang L, Wu H, Wang L, Zhang H, Lu J, Liang Z and Liu T: Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms. Cancer Lett. 398:24–36. 2017. View Article : Google Scholar : PubMed/NCBI
27	Yang L, Liu Y, Wang M, Qian Y, Dong X, Gu H, Wang H, Guo S and Hisamitsu T: Quercetin-induced apoptosis of HT-29 colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis. Mol Med Rep. 14:4559–4566. 2016. View Article : Google Scholar : PubMed/NCBI
28	Wang H, Chen B, Duan B, Zheng J and Wu X: miR-205 suppresses cell proliferation, invasion, and metastasis via regulation of the PTEN/AKT pathway in renal cell carcinoma. Mol Med Rep. 14:3343–3349. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chan LP, Liu C, Chiang FY, Wang LF, Lee KW, Chen WT, Kuo PL and Liang CH: IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC. Oncotarget. 8:56375–56388. 2017. View Article : Google Scholar : PubMed/NCBI
30	Cepeda MA, Evered CL, Pelling JJH and Damjanovski S: Inhibition of MT1-MMP proteolytic function and ERK1/2 signalling influences cell migration and invasion through changes in MMP-2 and MMP-9 levels. J Cell Commun Signal. 11:167–179. 2017. View Article : Google Scholar : PubMed/NCBI
31	Gur S, Sikka SC, Abdel-Mageed AB, Elmageed Abd ZY, Rezk B, Pankey E, Kadowitz PJ and Hellstrom WJ: Imatinib mesylate (gleevec) induces human corpus cavernosum relaxation by inhibiting Receptor Tyrosine Kinases (RTKs): Identification of new RTK targets. Urology. 82(745): e11–6. 2013.PubMed/NCBI
32	Puri N and Salgia R: Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog. 7:92008. View Article : Google Scholar : PubMed/NCBI
33	Liu TC, Jin X, Wang Y and Wang K: Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am J Cancer Res. 7:187–202. 2017.PubMed/NCBI